It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Non-pathogenic Neisseria are a reservoir of antimicrobial resistance genes for pathogenic Neisseria meningitidis and Neisseria gonorrhoeae. Men who have sex with men (MSM) are at risk of co-colonization with resistant non-pathogenic and pathogenic Neisseria. We assessed if the antimicrobial susceptibility of non-pathogenic Neisseria among MSM differs from a general population and if antimicrobial exposure impacts susceptibility. We recruited 96 participants at our center in Belgium: 32 employees, 32 MSM who did not use antibiotics in the previous 6 months, and 32 MSM who did. Oropharyngeal Neisseria were cultured and identified with MALDI-TOF–MS. Minimum inhibitory concentrations for azithromycin, ceftriaxone and ciprofloxacin were determined using E-tests® and compared between groups with non-parametric tests. Non-pathogenic Neisseria from employees as well as MSM were remarkably resistant. Those from MSM were significantly less susceptible than employees to azithromycin and ciprofloxacin (p < 0.0001, p < 0.001), but not ceftriaxone (p = 0.3). Susceptibility did not differ significantly according to recent antimicrobial exposure in MSM. Surveilling antimicrobial susceptibility of non-pathogenic Neisseria may be a sensitive way to assess impact of antimicrobial exposure in a population. The high levels of antimicrobial resistance in this survey indicate that novel resistance determinants may be readily available for future transfer from non-pathogenic to pathogenic Neisseria.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Institute of Tropical Medicine Antwerp, Department of Clinical Sciences, Antwerp, Belgium (GRID:grid.11505.30) (ISNI:0000 0001 2153 5088); University of Antwerp, Laboratory of Medical Microbiology, Wilrijk, Belgium (GRID:grid.5284.b) (ISNI:0000 0001 0790 3681)
2 Institute of Tropical Medicine Antwerp, Department of Clinical Sciences, Antwerp, Belgium (GRID:grid.11505.30) (ISNI:0000 0001 2153 5088)
3 Université Libre de Bruxelles, Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles, Pôle Hospitalier Universitaire de Bruxelles, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746)
4 Université Libre de Bruxelles, Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles, Pôle Hospitalier Universitaire de Bruxelles, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746); Université de Mons, Faculté de Médecine et Pharmacie, Mons, Belgium (GRID:grid.8364.9) (ISNI:0000 0001 2184 581X)
5 Institute of Tropical Medicine Antwerp, Department of Clinical Sciences, Antwerp, Belgium (GRID:grid.11505.30) (ISNI:0000 0001 2153 5088); University of Cape Town, Department of Medicine, Cape Town, South Africa (GRID:grid.7836.a) (ISNI:0000 0004 1937 1151)